Oncolix, Inc. (ONCX) financial statements (2021 and earlier)

Company profile

Business Address 14405 WALTERS ROAD
HOUSTON, TX 77014
State of Incorp. FL
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4942 15
Cash and cash equivalents4942 15
Prepaid expense81  2
Other undisclosed current assets314   
Total current assets:8892 17
Noncurrent Assets
Intangible assets, net (including goodwill)  4 
Intangible assets, net (excluding goodwill)  4 
Total noncurrent assets:  4 
TOTAL ASSETS:8892417
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:43226178114
Accounts payable6222612883
Accrued liabilities  5031
Other undisclosed accounts payable and accrued liabilities(19)   
Debt  126200
Other undisclosed current liabilities1,220   
Total current liabilities:1,263226304314
Noncurrent Liabilities
Liabilities, other than long-term debt1,268   
Deferred compensation liability, classified1,268   
Total noncurrent liabilities:1,268   
Total liabilities:2,531226304314
Stockholders' equity
Stockholders' equity attributable to parent, including:(1,642)(224)(301)(296)
Common stock10983
Additional paid in capital20,9605,150258183
Accumulated deficit(22,619)(5,377)(561)(483)
Other undisclosed stockholders' equity attributable to parent6(7)(7) 
Total stockholders' equity:(1,642)(224)(301)(296)
TOTAL LIABILITIES AND EQUITY:8892417

Income statement (P&L) ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 6 20
Other operating income 6  
Cost of revenue
(Cost of Goods and Services Sold)
(58)   
Gross profit:(58)6 20
Operating expenses(1,953)(106)(59)(258)
Other undisclosed operating loss (6)  
Operating loss:(2,011)(106)(59)(238)
Interest and debt expense437(4,710)1920
Loss from continuing operations before equity method investments, income taxes:(1,574)(4,816)(40)(217)
Other undisclosed loss from continuing operations before income taxes  (19)(20)
Net loss:(1,574)(4,816)(59)(238)
Other undisclosed net loss attributable to parent(1,783) (19)(20)
Net loss available to common stockholders, diluted:(3,357)(4,816)(78)(258)

Comprehensive Income ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(1,574)(4,816)(59)(238)
Comprehensive loss, net of tax, attributable to parent:(1,574)(4,816)(59)(238)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: